Researchers Propose Redefining Functional High‑Risk Myeloma as Progression Within 36 Months

The change would shift who is prioritized for early T‑cell redirecting treatments and dedicated clinical trials because their survival after relapse remains about two years or less.

Overview

A study published Monday in CANCER analyzed outcomes for 310 newly diagnosed patients treated with upfront quadruplet therapy followed by autologous stem cell transplantation and a median 3.5 years of follow‑up.
Investigators tested progression cutoffs at 12, 18, 24 and 36 months and found that progression within 36 months best identified patients whose post‑relapse survival stayed near two years or less.
Using the 36‑month cutoff (FHR36) captured about 16.4% of the cohort and included many patients who would not be labeled high‑risk by current staging systems.
Only 11 patients received T‑cell redirecting therapies as second‑line treatment and they had much better short‑term results than other therapies, but the small sample means those findings need validation in larger studies.
Authors recommend adopting FHR36 as a trial benchmark and prioritizing these patients for early T‑cell redirecting approaches, a change that could alter trial design, treatment access, and how clinicians counsel patients with early progression.